Forte Biosciences, Inc.
FBRX
$11.16
-$0.10-0.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.15% | -118.81% | 14.74% | 32.92% | -68.61% |
| Total Depreciation and Amortization | 15.38% | 30.00% | 0.00% | 0.00% | 11.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.33% | 155.08% | -32.38% | 0.38% | -0.25% |
| Change in Net Operating Assets | -108.24% | 214.77% | -517.97% | -109.55% | 10,587.27% |
| Cash from Operations | 2.84% | -3.46% | -23.07% | -37.01% | 10.96% |
| Capital Expenditure | 100.00% | -96.77% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | 201.10% | -- | -- | -- |
| Cash from Investing | -100.00% | 200.84% | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 833,255.56% | -99.98% | 883,233.33% | -- | -100.00% |
| Repurchase of Common Stock | 80.00% | -650.00% | 71.43% | 30.00% | 37.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.78% | -106.60% | -112,000.00% | -- | -- |
| Cash from Financing | 3,129.67% | -104.48% | 2,593,950.00% | 80.00% | -25.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 155.33% | 301.50% | 172.29% | -36.81% | 11.00% |